Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Oramed Pharmaceuticals (ORMP) Gross Profit (2016 - 2025)

Oramed Pharmaceuticals filings provide 7 years of Gross Profit readings, the most recent being $13000.0 for Q1 2025.

  • Quarterly Gross Profit changed N/A to $13000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $13000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $13000.0 for FY2025, N/A changed from the prior year.
  • Gross Profit hit $13000.0 in Q1 2025 for Oramed Pharmaceuticals, up from -$663000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $482000.0 in Q1 2023 and bottomed at -$663000.0 in Q3 2023.
  • Average Gross Profit over 3 years is $129000.0, with a median of $219000.0 recorded in 2022.
  • Peak annual rise in Gross Profit hit 534.21% in 2023, while the deepest fall reached 402.74% in 2023.
  • Oramed Pharmaceuticals' Gross Profit stood at $219000.0 in 2022, then crashed by 402.74% to -$663000.0 in 2023, then soared by 101.96% to $13000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Gross Profit are $13000.0 (Q1 2025), -$663000.0 (Q3 2023), and $482000.0 (Q2 2023).